79 related articles for article (PubMed ID: 20079687)
1. Response to Stegmann s, et Al. [J. Clin. Virol. 47 (1) (2010) 79-81].
Tan DH; Walmsley SL
J Clin Virol; 2010 Mar; 47(3):297-8. PubMed ID: 20079687
[No Abstract] [Full Text] [Related]
2. Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure.
Stegmann S; Manea ME; Charpentier C; Damond F; Karmochkine M; Laureillard D; Si-Mohamed A; Weiss L; Piketty C
J Clin Virol; 2010 Jan; 47(1):79-81. PubMed ID: 19962343
[TBL] [Abstract][Full Text] [Related]
3. Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients.
Charpentier C; Laureillard D; Sodqi M; Si-Mohamed A; Karmochkine M; Bélec L; Weiss L; Piketty C
J Clin Virol; 2008 Oct; 43(2):212-5. PubMed ID: 18760662
[TBL] [Abstract][Full Text] [Related]
4. Immunologic and virologic response of HIV-2 infection to antiretroviral therapy.
Clark NM; Dieng Sarr A; Sankalé JL; Kanki PJ; Kazanjian P; Winfield R; Markovitz DM
AIDS; 1998 Dec; 12(18):2506-7. PubMed ID: 9875594
[No Abstract] [Full Text] [Related]
5. Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations.
Mathiesen S; Roge BT; Weis N; Lundgren JD; Obel N; Gerstoft J
AIDS; 2004 Apr; 18(7):1076-8. PubMed ID: 15096815
[No Abstract] [Full Text] [Related]
6. Long-term maraviroc use as salvage therapy in HIV-2 infection.
Caixas U; Ferreira J; Marinho AT; Faustino I; Grilo NM; Lampreia F; Germano I; Monteiro EC; Pereira SA
J Antimicrob Chemother; 2012 Oct; 67(10):2538-9. PubMed ID: 22729923
[No Abstract] [Full Text] [Related]
7. Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study.
Sarfo FS; Bibby DF; Schwab U; Appiah LT; Clark DA; Collini P; Phillips R; Green I; Dittmar MT; Chadwick DR
J Antimicrob Chemother; 2009 Sep; 64(3):667-9. PubMed ID: 19549668
[No Abstract] [Full Text] [Related]
8. Interruptions may be beneficial.
AIDS Patient Care STDS; 2002 Oct; 16(10):512. PubMed ID: 12442736
[No Abstract] [Full Text] [Related]
9. Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients.
Landman R; Damond F; Gerbe J; Brun-Vezinet F; Yeni P; Matheron S
AIDS; 2009 Jan; 23(3):426-8. PubMed ID: 19114866
[TBL] [Abstract][Full Text] [Related]
10. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
[TBL] [Abstract][Full Text] [Related]
11. Failure of HIV-2 viral load assay in a severely immunodeficient patient: clinical and therapeutic management issues.
Fonquernie L; Eholié SP; Damond F; Lacombe K; Girard PM
Trans R Soc Trop Med Hyg; 2006 Mar; 100(3):282-4. PubMed ID: 16293278
[TBL] [Abstract][Full Text] [Related]
12. Amprenavir study results released.
AIDS Patient Care STDS; 1999 Dec; 13(12):754. PubMed ID: 10743545
[No Abstract] [Full Text] [Related]
13. Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2.
Rodés B; Toro C; Jiménez V; Soriano V
Clin Infect Dis; 2005 Jul; 41(2):e19-21. PubMed ID: 15983906
[TBL] [Abstract][Full Text] [Related]
14. Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.
Canestri A; Ghosn J; Wirden M; Marguet F; Ktorza N; Boubezari I; Dominguez S; Bossi P; Caumes E; Calvez V; Katlama C
Antivir Ther; 2006; 11(5):561-6. PubMed ID: 16964823
[TBL] [Abstract][Full Text] [Related]
15. Pediatric antiretroviral therapy: from research to practice.
Farley J; Vink P
Pediatr AIDS HIV Infect; 1996 Feb; 7(1):9-13. PubMed ID: 11361479
[No Abstract] [Full Text] [Related]
16. Individualized therapy for the treatment-experienced patient.
Walmsley S
AIDS Read; 2003 Jun; 13(6 Suppl):S11-5. PubMed ID: 12838742
[TBL] [Abstract][Full Text] [Related]
17. Triple therapy in previously untreated patients reduces viral load below limit of detection.
AIDS Patient Care STDS; 1996 Oct; 10(5):308-9. PubMed ID: 11361526
[No Abstract] [Full Text] [Related]
18. Dynamics of HIV-1 viral load in pregnancy.
Lillo FB; Bucceri AM; Bettini P; Farma E; Boeri E; Mastrorilli E; Rossi G; Vignali M; Varnier OE
AIDS; 1997 Sep; 11(11):1397-8. PubMed ID: 9302452
[No Abstract] [Full Text] [Related]
19. Drug resistance mutations as predictors of phenotypic zidovudine resistance in HIV-1 infection.
Chen P; Schmit JC; Arendt V; Plesseria JM; Lambert C; Fontaine E; Kirpach P; Ninove D; Schneider F; Hemmer R
AIDS; 1997 Oct; 11(12):1528-9. PubMed ID: 9342081
[No Abstract] [Full Text] [Related]
20. HIV type 2 demyelinating encephalomyelitis.
Moulignier A; Lascoux C; Bourgarit A
Clin Infect Dis; 2006 Jun; 42(11):e89-91. PubMed ID: 16652302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
